Table 6.
Group | Amyloid+
|
Amyloid−
|
p | ||||
---|---|---|---|---|---|---|---|
n | Mean (SD) | n80 (CI) | n | Mean (SD) | n80 (CI) | ||
CN | 47 | 0.95 (0.80) | 180 (103, 496) | 103 | 0.74 (0.75) | 257 (167, 473) | 0.189 |
EMCI | 67 | 1.26 (1.05) | 174 (113, 288) | 70 | 0.63 (0.81) | 421 (240, 857) | 0.012 |
LMCI | 88 | 1.84 (1.24) | 114 (81, 169) | 40 | 0.82 (0.91) | 309 (171, 701) | 0.005 |
AD | 68 | 2.37 (1.26) | 71 (49, 111) | 8 | 1.29 (1.27) | 243 (117, 751) | 0.061 |
Mean percentage of tissue atrophy (SD) and n80 (95% CI) for statistically defined region of interest numerical summaries are derived in CN, EMCI, LMCI, and AD groups over 12 months, amyloid+ [BL_SUVR_Summary ≥ 1.11] and amyloid− [BL_SUVR_Summary < 1.11]. n indicates the number of participants in the analysis. p Values estimate the evidence that the true 12-month n80 in amyloid− group is equal to or greater than that of the amyloid+ group (p < 0.05 marked in bold font).
Key: AD, Alzheimer’s disease; CI, confidence interval; CN, healthy controls; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; SD, standard deviation.